Ornithine alpha ketoglutarate (DrugBank: Ornithine)
2 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
245 | プロピオン酸血症 | 1 |
251 | 尿素サイクル異常症 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00645879 (ClinicalTrials.gov) | July 2008 | 25/3/2008 | Anaplerotic Therapy in Propionic Acidemia | Safety & Efficacy of Investigational Products: Ornithine Alpha-ketoglutarate, Glutamine, or Disodium Citrate on Hyperammonemia in Propionic Acidemia. | Propionic Acidemia | Drug: ornithine alpha ketoglutarate;Drug: glutamine;Drug: disodium citrate | Nicola Longo | National Institutes of Health (NIH);National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | 5 Years | 12 Years | Both | 3 | Phase 1 | United States |